webinar register page

Webinar banner
Data & Perspectives — Investigators Discuss the Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with Hematologic Cancers
A CME/NCPD-Accredited Virtual Event in Partnership with the 2022 Pan Pacific Lymphoma Conference

After registering, you will receive a Zoom (email) confirmation notice with a unique "click to join" webinar link for day of program viewing of this event. This email will also contain instructions for phone users. PLEASE DO NOT SHARE YOUR ZOOM CONFIRMATION EMAIL OR VIEWING LINK WITH OTHERS.


Tuesday, August 9, 2022, 5:00 PM - 6:30 PM Eastern Time

MODULE 1: Current and emerging role of CAR T-cell therapy for aggressive and indolent lymphomas

MODULE 2: Biologic rationale for, available data with and potential clinical use of CD20 x CD3 bispecific antibodies for lymphoma

MODULE 3: Optimal integration of BCMA-directed CAR T-cell therapy into the care of patients with multiple myeloma (MM)

MODULE 4: BCMA and non-BCMA bispecific antibodies under investigation for MM

Ajai Chari, MD
Ian W Flinn, MD, PhD
Nikhil C Munshi, MD
Laurie H Sehn, MD, MPH

Neil Love, MD

Aug 9, 2022 05:00 PM in Eastern Time (US and Canada)

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Dr Neil Love.